TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32838773

Group type: EXPERIMENTAL
Intervention: Talking Time intervention (telephone-based support, including preliminary talk, information booklet, six structured meetings, and written self-evaluation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (usual individual self-organized care)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (not specified)
Number of subjects: 38
Study: 35193803

Group type: EXPERIMENTAL
Intervention: Topical application of 0.5 g/L tranexamic acid (TXA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with 0.9% sodium chloride
Number of subjects: 40
Study: 33637543

Group type: EXPERIMENTAL
Intervention: Willingness to participate in a cancer surveillance RCT
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Reasons for participation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Reasons for declining participation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Perception of cancer research
Number of subjects: 130
Study: 36457073

Group type: EXPERIMENTAL
Intervention: 10-week multifaceted lifestyle intervention including nutrition and physical activity education, produce harvesting, cooking demonstrations, nutrition counseling, and kinetic activities.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 33421230

Group type: EXPERIMENTAL
Intervention: Oral sucrosomial iron (SI) 28 mg daily for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (matched HFrEF patients)
Number of subjects: 25
Study: 34536949

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (Abi + P) + ADT
Number of subjects: 200

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 200
Study: 35392847

Group type: EXPERIMENTAL
Intervention: Mindful with Your Baby intervention
Number of subjects: 17
Study: 32621877

Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI combined with clinical prognostic factors (CPF)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI combined with CPF
Number of subjects: 85

Group type: COMPARATOR
Intervention: Individual MRI parameters (D, Ktrans, Ve)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Stage of cancer
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: D, Ktrans, Ve
Number of subjects: 85
Study: 33068669

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right DLPFC at 2 mA for 20 min
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham tDCS over the right DLPFC
Number of subjects: 21
Study: 32359056

Group type: EXPERIMENTAL
Intervention: Cancer warning labels applied to alcohol containers for 1 month at the intervention site.
Number of subjects: 2049
Study: 34636216

Group type: EXPERIMENTAL
Intervention: Syringe irrigation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tornado Brush
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MM‐Seal
Number of subjects: 72
Study: 32928122

Group type: EXPERIMENTAL
Intervention: Barrier box (BB)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (C) without barrier box
Number of subjects: 78
Study: 33637605

Group type: EXPERIMENTAL
Intervention: D-allulose 7.5 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: D-allulose 10 g
Number of subjects: 30
Study: 32938620

Group type: EXPERIMENTAL
Intervention: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B1)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B2)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with trastuzumab
Number of subjects: 71
Study: 34694437

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BCP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: delNido cardioplegia (dNCP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Custodiol cardioplegia (CCP)
Number of subjects: 27
Study: 34349503

Group type: EXPERIMENTAL
Intervention: Test formulation of regorafenib (40 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Reference formulation of regorafenib (Stivarga®, 40 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both formulations of regorafenib (40 mg)
Number of subjects: 66
Study: 32941498

Group type: EXPERIMENTAL
Intervention: Consumer-grade wearable (Huami Arc) with a threshold of 10 units
Number of subjects: 41

Group type: COMPARATOR
Intervention: Research-grade actigraph (Philips Actiwatch Spectrum)
Number of subjects: 41
Study: 35864302

Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and Dimenhydrinate 40 mg
Number of subjects: 795

Group type: COMPARATOR
Intervention: Cinnarizine 20 mg
Number of subjects: 795

Group type: COMPARATOR
Intervention: Betahistine dimesylate 12 mg
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Cinnarizine/Dimenhydrinate group
Number of subjects: 795

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 795
Study: 33784411

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220 µg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 34915109

Group type: EXPERIMENTAL
Intervention: Higher serum ACE2 activity
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Serum ACE2 activity
Number of subjects: 228
Study: 33531881

Group type: EXPERIMENTAL
Intervention: Intensified periprocedural physiotherapy including inspiratory muscle training
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard postprocedural physiotherapy (control group)
Number of subjects: 108
Study: 32810089

Group type: EXPERIMENTAL
Intervention: Intermittent kangaroo mother care for seven days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intermittent kangaroo mother care
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care therapy
Number of subjects: 140
Study: 34654905

Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 143
Study: 32612308

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 3 days
Number of subjects: 4002

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 4002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4002
Study: 36417057

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg EOD
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg EOD (after switching from placebo)
Number of subjects: 695
Study: 34137551

Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Veress Needle Insertion (VNI)
Number of subjects: 400
Study: 32991399

Group type: EXPERIMENTAL
Intervention: Light vegetarian diet (LVD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Qingjiang Tiaochang Recipe (QJTCR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo + diet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine + diet
Number of subjects: 90
Study: 36081341

Group type: EXPERIMENTAL
Intervention: Ways of Being (WoB)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Typical museum website (Ash)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Both groups (WoB and Ash)
Number of subjects: 463
Study: 33972795

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32347777

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3) administered intradermally or intramuscularly
Number of subjects: 89
Study: 34871580

Group type: EXPERIMENTAL
Intervention: 1.62% transdermal testosterone gel
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Matching placebo gel
Number of subjects: 6000
Study: 33829679

Group type: EXPERIMENTAL
Intervention: VL10%
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: VL30%
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: VL45%
Number of subjects: 33
Study: 35791734

Group type: EXPERIMENTAL
Intervention: Fish oil (ω‐3 fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (ω‐6 fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (ω‐6 fatty acids) after washout
Number of subjects: 0
Study: 32681263

Group type: EXPERIMENTAL
Intervention: Households experiencing moderate hunger
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Inappropriate feeding practices
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Moderate household hunger
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Wasting
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Composite index of anthropometric failure (CIAF)
Number of subjects: 525
Study: 35543281

Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg with Al(OH)3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg with CpG/Al(OH)3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg with Al(OH)3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg with CpG/Al(OH)3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg with Al(OH)3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg with CpG/Al(OH)3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg unadjuvanted
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg with CpG/Al(OH)3 (month 0,2 cohort)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose seasonal inactivated influenza vaccine (SIIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF formulations
Number of subjects: 0
Study: 33148479

Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 mg plus Tamoxifen 20 mg (A+T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abemaciclib 200 mg plus prophylactic loperamide (A-200)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abemaciclib 150 mg every 12 hours (A-150)
Number of subjects: 0
Study: 33157186

Group type: EXPERIMENTAL
Intervention: Circumferential radiofrequency ablation
Number of subjects: 197
Study: 36219407

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg daily plus Oxycodone 10 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Quetiapine (100 mg to 400 mg) plus Oxycodone 10 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Quetiapine (100 mg to 400 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo plus Oxycodone 10 mg
Number of subjects: 25
Study: 34492561

Group type: EXPERIMENTAL
Intervention: Mental fatigue induced using the Stroop colour‐word task
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not mentally fatigued)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mental fatigue
Number of subjects: 48
Study: 33966009

Group type: EXPERIMENTAL
Intervention: Squat Jump Force-Velocity Profile
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Squat Jump Load-Velocity Profile
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Force-Velocity Profiles created with peak force and relative peak force
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Force-Velocity Profiles created with mean and relative mean forces
Number of subjects: 18
Study: 32183908

Group type: EXPERIMENTAL
Intervention: Positive deviance intervention for promoting dual-method use
Number of subjects: 960

Group type: COMPARATOR
Intervention: Control group (standard approach)
Number of subjects: 960
Study: 33941921

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with FGFR inhibitors
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with PARP inhibitors
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with TORC1/2 inhibitors
Number of subjects: 135

Group type: COMPARATOR
Intervention: Durvalumab monotherapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Number of subjects: 135
Study: 32172602

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (moderate continuous training)
Number of subjects: 50
Study: 35499452

Group type: EXPERIMENTAL
Intervention: Sustained pre-manipulative thrust C0-1
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sustained cervical end of range rotation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham position
Number of subjects: 19
Study: 32469260

Group type: EXPERIMENTAL
Intervention: Beetroot extract (600 mg in capsule)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (600 mg starch in capsule)
Number of subjects: 12
Study: 32173607

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) 30 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) 60 L/min
Number of subjects: 10
Study: 35728808

Group type: EXPERIMENTAL
Intervention: VL15
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VL25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VL50
Number of subjects: 50
Study: 32912274

Group type: EXPERIMENTAL
Intervention: 200 mg elacestrant QD (escalated to 400 mg after 14 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mg elacestrant QD
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Elacestrant (200 mg and 400 mg QD)
Number of subjects: 16
Study: 35172277

Group type: EXPERIMENTAL
Intervention: HIIT + RT
Number of subjects: 50

Group type: COMPARATOR
Intervention: MICT + RT
Number of subjects: 50
Study: 33971441

Group type: EXPERIMENTAL
Intervention: Ethanol extraction combined with SERS
Number of subjects: 0
Study: 32859100

Group type: COMPARATOR
Intervention: Pooled Intervention (Enhanced and Traditional)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Enhanced group
Number of subjects: 116
Study: 34865095

Group type: EXPERIMENTAL
Intervention: Local oxygen‐ozone therapy plus medical treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 25
Study: 33826027

Group type: EXPERIMENTAL
Intervention: Durvalumab plus EP
Number of subjects: 34

Group type: COMPARATOR
Intervention: EP
Number of subjects: 34
Study: 32200541

Group type: EXPERIMENTAL
Intervention: Totally intracorporeal neobladder techniques (Karolinska-modified Studer neobladder, USC-modified Studer neobladder, pyramid pouch, Y-pouch, vesica Ileale Padovana)
Number of subjects: 0
Study: 36366308

Group type: EXPERIMENTAL
Intervention: FAKHRAVAC
Number of subjects: 435

Group type: COMPARATOR
Intervention: BBIBP‐CorV
Number of subjects: 435
Study: 34166055

Group type: EXPERIMENTAL
Intervention: Cognitive distortions
Number of subjects: 150
Study: 35665526

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for binge-eating disorder (DBT-BED)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT+)
Number of subjects: 175
Study: 34086514

Group type: EXPERIMENTAL
Intervention: Carboplatin, docetaxel, and capecitabine (CTX)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Epirubicin, oxaliplatin, and capecitabine (EOX)
Number of subjects: 98
Study: 33531359

Group type: EXPERIMENTAL
Intervention: Occupational UVR exposure (≥20 years)
Number of subjects: 38375

Group type: EXPERIMENTAL
Intervention: Highest cumulative UVR exposure
Number of subjects: 38375

Group type: COMPARATOR
Intervention: Control group (no UVR exposure)
Number of subjects: 38375
Study: 33068349

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX-UE 10), applied once every 2 days for a total of 4 times
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine anti-infection and symptomatic and supportive treatment (Control Group)
Number of subjects: 80
Study: 34930810

Group type: EXPERIMENTAL
Intervention: The Real Cost ads
Number of subjects: 623

Group type: COMPARATOR
Intervention: Control videos
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Single-item PME measure
Number of subjects: 623
Study: 32740214

Group type: EXPERIMENTAL
Intervention: Fractionally ablative Er:YAG resurfacing, 3 treatments at monthly intervals
Number of subjects: 12
Study: 35473348

Group type: EXPERIMENTAL
Intervention: Low dosage of MKA plus lifestyle modifications
Number of subjects: 117

Group type: COMPARATOR
Intervention: Lifestyle modifications
Number of subjects: 117
Study: 34187853

Group type: EXPERIMENTAL
Intervention: Combination of androgen deprivation therapy (ADT), 6 cycles of radium-223 q28 days, conventionally fractionated prostate radiotherapy (74 Gy) and simultaneous integrated boost to pelvic lymph nodes (60 Gy)
Number of subjects: 30
Study: 36165862

Group type: EXPERIMENTAL
Intervention: Nutrition Bio-shield Superfood (NBS) 4.5 gr daily for 14 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo three times a day for 14 days
Number of subjects: 70
Study: 34153543

Group type: EXPERIMENTAL
Intervention: Methylene blue photosensitizer (MBP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (AA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Er, Cr: YSGG laser (ECL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 35981113

Group type: EXPERIMENTAL
Intervention: Massage and progressive relaxation exercises
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study: 35799145

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 710
Study: 34364385

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 621

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 621
Study: 33109241

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) session, cuff inflation and deflation (5 min each repeated 3 times) performed before the exercise by inflating cuffs to the non‐dominant leg and arm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham session, cuffs were inflated for a short period (1 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session, no cuffs were involved
Number of subjects: 20
Study: 35500450

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Group Psychotherapy (GPT)
Number of subjects: 419
Study: 33960065

Group type: EXPERIMENTAL
Intervention: Virtual reality glass showing ultrasound images of the foetus during labour
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine procedures
Number of subjects: 100
Study: 32033078

Group type: EXPERIMENTAL
Intervention: Reduced fat (2%) milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sugar-sweetened soda
Number of subjects: 30
Study: 36191556

Group type: EXPERIMENTAL
Intervention: 50% N2O/50% oxygen (N2O group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 50% air/50% oxygen (placebo group)
Number of subjects: 44
Study: 32073181

Group type: EXPERIMENTAL
Intervention: Formal attire (tie and buttoned‐up white coat)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Casual attire (without tie or white coat)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall preference for physician
Number of subjects: 105
Study: 36295512

Group type: EXPERIMENTAL
Intervention: Myrrh mouthwash
Number of subjects: 35

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 35
Study: 33663518

Group type: EXPERIMENTAL
Intervention: Care to Quit intervention (implementation of smoking cessation care models/pathways)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Care to Quit intervention
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 2160
Study: 35978223

Group type: EXPERIMENTAL
Intervention: Non-irradiated teeth (NoRad)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Irradiated teeth with ER approach (RadER)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Irradiated teeth with SE approach (RadSE)
Number of subjects: 76
Study: 34370912

Group type: EXPERIMENTAL
Intervention: In-office whitening agent (Opalescence Boost 35%) with light irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office whitening agent (Opalescence Boost 35%) without light irradiation
Number of subjects: 0
Study: 36002025

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) combined with SmartMind game
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 33090910

Group type: EXPERIMENTAL
Intervention: Whole body passive heating (42°C bath)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dynamic lower body exercise (semi-recumbent stepping) at matched heart rate intensity (HRMATCHED)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dynamic lower body exercise (semi-recumbent stepping) at higher intensity (53% V̇o2max)
Number of subjects: 15
Study: 36203819

Group type: EXPERIMENTAL
Intervention: Remimazolam 0.2 mg kg‐1
Number of subjects: 104

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 104
Study: 34154433

Group type: EXPERIMENTAL
Intervention: Peripheral nerve grafting and acidic fibroblast growth factor (aFGF) infusion
Number of subjects: 4

Group type: COMPARATOR
Intervention: Spinal cord hemisection surgery (control)
Number of subjects: 4
Study: 35555099

Group type: COMPARATOR
Intervention: High-Iron milk formula (HI) with 480 mg Fe/kg milk solid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-Iron milk formula supplemented with inulin (HIP) at 6% of milk solid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-Iron milk formula with inulin and Lactobacilus agilis (HIS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Iron-adequate milk formula (AI) with 60 mg Fe/kg milk solid
Number of subjects: 24
Study: 32184382

Group type: EXPERIMENTAL
Intervention: 1 cm heel lift
Number of subjects: 14